{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:30:11Z","timestamp":1761129011817},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/mou.0b013e328356ac0a","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T13:15:35Z","timestamp":1342703735000},"page":"427-431","source":"Crossref","is-referenced-by-count":6,"title":["Indication and timing of cystectomy in high-risk bladder cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Thierry","family":"Lebret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20210206","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/j.1464-410X.2010.09347.x","article-title":"Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma.","volume":"106","author":"Dalbagni","year":"2010","journal-title":"BJU Int"},{"key":"R3-14-20210206","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for nonmuscle-invasive bladder cancer.","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"R4-14-20210206","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"R5-14-20210206","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy.","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"R6-14-20210206","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMsa012337","article-title":"Hospital volume and surgical mortality in the United States.","volume":"346","author":"Birkmeyer","year":"2002","journal-title":"N Engl J Med"},{"key":"R7-14-20210206","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000020233","article-title":"Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer.","volume":"37","author":"Lebret","year":"2000","journal-title":"Eur Urol"},{"key":"R8-14-20210206","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1440-1827.2011.02694.x","article-title":"Association between the expression pattern of p16, pRb and p53 and the response to intravesical Bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder.","volume":"61","author":"Sato","year":"2011","journal-title":"Pathol Int"},{"key":"R9-14-20210206","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2006.06.006","article-title":"HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours.","volume":"51","author":"Lebret","year":"2007","journal-title":"Eur Urol"},{"key":"R10-14-20210206","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.eururo.2006.07.056","article-title":"Radical cystectomy - often too late Yes but.","volume":"50","author":"Studer","year":"2006","journal-title":"Eur Urol"},{"key":"R11-14-20210206","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, nonmuscle-invasive bladder cancer and tumour progression: a systematic review.","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"R12-14-20210206","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"R13-14-20210206","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"EORTC Genito-Urinary Tract Cancer GroupMaintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial.","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"R14-14-20210206","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0022-5347(05)65157-9","article-title":"Contemporary management of stage T1 transitional cell carcinoma of the bladder.","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"R15-14-20210206","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1464-410X.2009.08375.x","article-title":"A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy.","volume":"104","author":"Whitson","year":"2009","journal-title":"BJU Int"},{"key":"R16-14-20210206","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.eururo.2003.10.006","article-title":"Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy.","volume":"45","author":"Schrier","year":"2004","journal-title":"Eur Urol"},{"key":"R17-14-20210206","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk nonmuscle invasive bladder cancer.","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"R19-14-20210206","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.juro.2010.03.022","article-title":"Nonprimary pT1 nonmuscle invasive bladder cancer treated with Bacillus Calmette-Guerin is associated with higher risk of progression compared to primaryT1 tumors.","volume":"184","author":"Alkhateeb","year":"2010","journal-title":"J Urol"},{"key":"R20-14-20210206","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.urology.2007.02.064","article-title":"Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion.","volume":"69","author":"Lee","year":"2007","journal-title":"Urology"},{"key":"R21-14-20210206","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","article-title":"Quantification of the survival benefit of early versus deferred cystectomy in high-risk nonmuscle invasive bladder cancer (T1 G3).","volume":"27","author":"Hautmann","year":"2009","journal-title":"World J Urol"},{"key":"R22-14-20210206","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"R24-14-20210206","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1309\/94B6-8VFB-MN9J-1NF5","article-title":"Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens.","volume":"113","author":"Cheng","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"R25-14-20210206","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical Bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"R27-14-20210206","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with Bacillus Calmette-Guerin.","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"R28-14-20210206","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","article-title":"The effect of gender on response to Bacillus Calmette-Guerin therapy for patients with nonmuscle-invasive urothelial carcinoma of the bladder.","volume":"106","author":"Boorjian","year":"2010","journal-title":"BJU Int"},{"key":"R29-14-20210206","first-page":"1026","article-title":"Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy BJU I","volume":"109","author":"Segal","year":"2012","journal-title":"nt"},{"key":"R30-14-20210206","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer.","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"R31-14-20210206","first-page":"126","article-title":"Prognosis of T1G3 bladder cancer: how well can we predict progression Eur U","volume":"62","author":"Witjes","year":"2012","journal-title":"rol"},{"key":"R34-14-20210206","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to Bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review.","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0b013e328356ac0a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:09:06Z","timestamp":1620965346000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042307-201209000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0b013e328356ac0a","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}